Sagespring Wealth Partners LLC Takes $832,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Sagespring Wealth Partners LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,245 shares of the medical research company's stock, valued at approximately $832,000.

Several other hedge funds also recently bought and sold shares of the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth about $30,000. Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.5 %

Shares of NYSE EW traded up $0.36 on Friday, reaching $71.56. 3,235,636 shares of the company's stock traded hands, compared to its average volume of 4,927,071. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business's 50 day simple moving average is $71.31 and its two-hundred day simple moving average is $70.85. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a market cap of $42.07 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on EW. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Truist Financial dropped their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $78.55.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.